Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

Columbia University

Status

Completed

Conditions

Celiac Disease

Treatments

Drug: Placebo

Drug: Rifaximin

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01137955

AAAB6531

IRB-AAAB6531(Y3M00) (Other Identifier)

Details and patient eligibility

About

Celiac disease is a condition in which the small intestine is damaged by gluten, the storage protein of wheat and similar proteins in barley and rye. The disease can cause different symptoms such as diarrhea, bloating, abdominal pain and weight loss. The majority of patients respond to a gluten-free diet. However some patients (5-30%) have persistent symptoms and are considered to be poor responders to the diet. Bacterial overgrowth in the small intestine accounts for some of the refractory patients.

This study seeks to determine if antibiotic therapy with rifaximin relieves the symptoms of patients who are poorly responsive to a gluten-free diet and whether this impacts their breath test results.

Full description

A symptom questionnaire will be administered at study initiation, 2 weeks and 12 weeks. Patients will undergo a breath test which involves drinking a sugar (lactulose) solution and breathing into a machine. This technique will identify the presence of bacteria in the small intestine. They will be randomly selected to receive either an antibiotic (rifaximin) or placebo three times a day for 10 days to treat their bacterial overgrowth.

Enrollment

50 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult patients age 18 or older
Biopsy proven celiac disease
Persistent symptoms of diarrhea, gas, bloating and/or cramping despite a gluten free diet for at least 1 month
Women that are not pregnant or lactating can be included. All women must have a documented negative pregnancy test at the initiation of the study. Women who become pregnant during the study will be asked to discontinue the study drug and will be followed up until the outcome of pregnancy is known. Women of child bearing potential must be practicing an effective method of birth control (eg: prescription oral contraceptive, contraceptive injections, intra-uterine device (IUD), double barrier method, contraceptive patch, male sterilization) before entry and throughout the treatment period.

Exclusion criteria

antibiotic use for any indication within preceding one month
use of bismuth compounds within preceding month
concomitant use of pancreatic supplements
concomitant use of antispasmodics
concomitant use of immunomodulators such as corticosteroids, budesonide, alkylating agents and antimetabolites.
concomitant use of probiotics
concomitant use of prokinetic agents
concomitant use of 5-hydroxytryptamine receptor (5HT3) antagonists,5-hydroxytryptamine receptor (5HT4) antagonists.
concomitant use of antimotility agents (e.g loperamide)
concomitant use of antidiarrheal agents
diagnosed microscopic colitis or inflammatory bowel disease
other causes of malabsorption: pancreatic insufficiency, giardiasis and enteropathy associated with T cell lymphoma.
other diseases: renal or hepatic insufficiency.
pregnant patients and lactating females. In addition women of child bearing age will be excluded if they are not using one of the methods of contraception like oral contraceptives,intrauterine device.

and double barrier methods.
patients with tuberculosis or a positive purified protein derivative (PPD) test and infection with other mycobacterial diseases.
allergy and/or potential emergence of drug resistance to rifampicin and rifamycin compounds.